Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

HER2+ Metastatic Breast Cancer: Safety Data With T-DXd

July 25th 2022

Homing in on trastuzumab deruxtecan, T-DXd, expert panelists review recent safety data in the setting of HER2+ metastatic breast cancer.

Novel Treatment Approaches to Relapsed/Refractory HR+ Breast Cancer

July 25th 2022

Comprehensive insight on novel treatment approaches in the setting of relapsed/refractory HR+/HER2- breast cancer, including oral SERDs, SERMs, and ER PROTAC degraders.

Metastatic TNBC: Safety, Efficacy, and Quality of Life With Sacituzumab Govitecan

July 25th 2022

Comprehensive discussion on the safety and efficacy profile of the antibody-drug conjugate (ADC) sacituzumab govitecan and managing ADC-related adverse events in patients with mTNBC.

CDK4/6 Inhibitors Could Fill Treatment Void for Patients with HR+/HER2- Early Breast Cancer

July 22nd 2022

Joyce O'Shaughnessy, MD, outlines the current role and ongoing research of CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive, HER2-negative early stage breast cancer.

Overcoming Resistance in HR+/HER2- mBC: Other Novel Targeted Agents

July 20th 2022

Broad perspectives on various novel mechanisms of action that may address acquired resistance to therapies for HR+/HER2- metastatic breast cancer.

Overcoming Resistance in HR+/HER2- mBC: Novel ADC and SARM Therapy

July 20th 2022

Considerations for how novel antibody drug conjugates (ADCs) and selective androgen receptor modulators (SARMs) may respectively address mechanisms of resistance within HR+/HER2- metastatic breast cancer.

Trastuzumab Deruxtecan Approved in Europe for HER2+ Metastatic Breast Cancer Treated With 1 or More Prior Anti–HER2-Based Regimens

July 19th 2022

The European Commission has approved fam-trastuzumab deruxtecan-nxki for use as a single agent in adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received at least 1 anti–HER2-based regimen.

Alpelisib/Fulvestrant Combination Wins Philippine Approval for PIK3CA-Mutated, HR+/HER2– Metastatic Breast Cancer

July 18th 2022

The Philippine FDA has granted approval to alpelisib in combination with fulvestrant for the treatment of patients with PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer.

Europe Validates Marketing Application for Trastuzumab Duocarmazine for Metastatic HER2+ Breast Cancer

July 18th 2022

The European Medicines Agency has validated the marketing authorization application for trastuzumab duocarmazine for the treatment of patients with HER2-positive unresectable, locally advanced or metastatic breast cancer.

Clinical Scenario: mTNBC Treated With Chemotherapy Then Sacituzumab Govitecan

July 18th 2022

After reviewing a patient scenario of relapsed/refractory metastatic TNBC, expert oncologists elucidate use of sacituzumab govitecan in this setting.

Is There a Role for CDK4/6 Inhibition in HR+/HER2+ Breast Cancer?

July 18th 2022

Shifting their focus to the HR+/HER2+ setting of breast cancer, expert panelists consider the potential of CDK4/6 inhibition in light of clinical trial data.

Overview of Treatment Options in HER2+ Metastatic Breast Cancer

July 18th 2022

Shared insight on the treatment armamentarium for patients diagnosed with HER2+ metastatic breast cancer.

Perspectives on the Current Treatment Landscape of TNBC

July 18th 2022

Expert oncologists share insight on the prognosis of triple-negative breast cancer (TNBC) and broadly review current treatment options for patients.

Frontline Combination Strategies in HR+/HER2- BC

July 18th 2022

A brief review of frontline combination strategies in the context of multiple driver pathways in HR+/HER2- breast cancer.

Escalation or Deescalation of Therapy in Early-Stage HER2+ Breast Cancer

July 18th 2022

Before closing out their discussion on early-stage HER2+ breast cancer, expert oncologists define the value of escalating or deescalating therapy.

Optimized Therapy Requires More Than Binary Understanding of HER2 Positivity in Metastatic Breast Cancer

July 16th 2022

Neratinib-based combinations, antibody-drug conjugates, and bispecific antibodies represent novel and effective treatment options for patients with pretreated HER2-mutant and HER2-low metastatic breast cancer, but the successful integration of these regimens into care will require further investigation into current definitions of HER2 positivity.

ADCs With Non-Cytotoxic Payloads May Represent the Future of HER2+ Breast Cancer Treatment

July 16th 2022

The emergence of novel agents like trastuzumab deruxtecan and tucatinib in the HER2-positive breast cancer treatment paradigm have served to markedly improve outcomes for those with this disease, according to Mark Pegram, MD, who added that the future looks bright.

Intrinsic Tumor Subtyping Is Key To Breast Cancer Treatment

July 15th 2022

Charles M. Perou, PhD, discusses the role of intrinsic tumor subtyping in treatment decisions and outcomes for patients with breast cancer.

Treatment Strategies Evolve With Increased Disease Specification in HER2+ Breast Cancer

July 15th 2022

Adrienne G. Waks, MD, highlights clinical trials that are studying emerging treatment escalation and de-escalation strategies in early stage HER2-positive breast cancer, elaborates on the future of immunotherapy in this setting, and explains the significance of establishing new biomarkers.

Ovarian Function Suppression Drives Chemotherapy Benefits in Premenopausal HR+/HER2- Breast Cancer

July 15th 2022

Premenopausal patients with early hormone receptor–positive, HER2-negative breast cancer can benefit from chemotherapy, although it is still debatable whether that benefit stems from the chemotherapy itself or the ovarian function suppression that happens as a result of chemotherapy.